Pazopanib as Second-line Antiangiogenic Treatment in Metastatic Renal Cell Carcinoma After Tyrosine Kinase Inhibitor (TKI) Failure: A Phase 2 Trial Exploring Immune-related Biomarkers for Testing in the Post-immunotherapy/TKI Era

1. Bellmunt, J.
2. Esteban, E.
3. Del Muro, X.G.
4. Sepúlveda, J.M.
5. Maroto, P.
6. Gallardo, E.
7. Del Alba, A.G.
8. Etxaniz, O.
9. Guix, M.
10. Larriba, J.L.G.
11. Arranz, J.A.
12. Redrado, M.
13. Calvo, A.